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ABSTRACT

Up to date, a plethora of protein based materials are used as implants to stimulate tissue
regeneration or fillers to alleviate tissue or organ impairment. This includes glottal insufficiency,
urinary bladder incontinence and especially in cosmetic industrial to improve facial contour.
Once in vivo, protein-based materials are decomposed by cell secreted matrix metalloproteinases
(MMP) and lose their volume within months [1, 2, 3, 4]. By introducing MMP inhibitor (MMPI),
the extent of material degradation over time may be reduced. In this dissertation, the
development of cell-based assay capable of identifying MMPI candidates for protein-based
implant lifetime prolongation is described. To visualize the degradation, DQ-gelatin, (heavily
fluorescence labeled gelatin that emits fluorescence signal proportional to its degradation) was
used to represent the implant material. This gelatin was co-cultured with NIH-3T3 in a 96-well
plate supplemented with growth media under standard tissue culture condition (5% CO2, 95%
humidity at 37°C). Number of seeded cells, DQ-gelatin concentration and experiment run time
were varied to optimize signal-to-noise ratio whilst taking into account more than 80% of seeded
cells must remain viable. With optimized parameters, 0.8 million cells cultured on cell adhesion
support scaffold in presence of 50 µg/mL DQ-gelatin for 5 days, the efficacy of BB-94 and
TIMP-1 as synthetic and natural MMPI candidate were investigated. Both BB-94 and TIMP-1
were tested at different concentrations according to their IC50 and the approximated amount of
MMPs in tissue fluid, 20-1000 nM and 0.1-2 µg/mL respectively, to determine their most
efficient dosage. BB-94 and TIMP-1 demonstrated maximum potential at 72.59±4.75 % and
60.00±27.41 % at the concentration of 1000 nM and 2 µg/mL respectively. Statistical Analysis
could not detect the significant difference from varying MMP inhibitor concentration, therefore,
their concluded most efficient dosage in our experiment is the lowest concentration used for

testing. Because our assay generated reliable statistically distinct signals and are capable of
detecting quantitative inhibitory efficacy of MMP inhibitors, we believe our novel cell-based
assay is a feasible method for MMP inhibitor screening that could better represent the complex
degradation process of protein-based implants in biological systems than the current
conventional enzyme-based methods.
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CHAPTER 1: INTRODUCTION

At present, there are numerous protein-based materials applications [1, 5-11], both in research
developmental stage and in clinical use. Many are utilized for regenerative purposes such as for
tissue growth stimulation in cardiac muscle, nerve and cartilage, while some are used as fillers to
alleviate glottal insufficiency, urinary incontinence and even in while cosmetic industry to
reduce wrinkles. These materials doubtlessly create a lot of impact in our society; however, in
most cases, their lifetimes are only a few months after they are implanted. Therefore, it would be
very beneficial to be able to prolong their retention time in vivo. In this way, the healing efficacy
of the implant is improved, the duration that the implant provides satisfactory effects would be
extended and patients would not have to go through the surgical process as often, consequently,
improving the community living standard.

Once inside the body, protein based materials are degraded the same way as extracellular matrix
(ECM) turnover [12], which is by enzymatic digestion. These specific groups of enzymes are
generally referred to as matrix metalloproteinases (MMPs) [13]. They are secreted by both
residential cells and infiltrated cells recruited during inflammation after wounds through
laceration, injection or damage of tissue has taken place. By inhibiting MMP activities, the
retention time of protein-based implants in vivo could be extended. For this reason, our research
group is interested in identifying suitable MMP inhibitors (MMPis) and has developed a novel
cell based assay for MMPi screening that can analyze the inhibitory effectiveness of each
inhibitor.
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MMPs are zinc dependent enzymes; all enzymes of this family share a specific structural motif,
which is zinc binding domain [14, 15]. By introducing agents capable of forming a complex with
MMPs at this structure, the proteolytic activity of MMPs may be inhibited. These agents are
referred to as MMP inhibitors. There exist many types of MMPi in nature, the major endogenous
inhibitors in tissue are the tissue inhibitors of metalloproteinases (TIMPs) [16]. Due to MMP upregulation during tumor invasion, a large variety of MMP inhibitors has been synthesized as
anticancer drugs. They are effective and relatively inexpensive when compare to natural MMP
inhibitors [14].

The current technique most associated with the studies of MMP and their inhibitors is
zymography [17]. Zymography or substrate zymography is an electrophoretic method that has
been extensively used to study ECM degrading enzymes. It visualizes proteolytic activity based
on substrate digestion [18]. Zymography does not give accurate quantification of enzymatic
activity [19] nor does it resembles enzymatic degradation in nature. In this research, we construct
a cell-based assay prototype capable of screening MMP inhibitors. It provides quantitative data
on degradation inhibition efficacy together with the effect of the inhibitor on cell viability. By
focusing on cellular modulated degradation, the information obtained should resemble more of
the material breakdown after implantation. For substances intended to be used in vivo, they are
generally introduced into cell culture to evaluate the substance effect on cell apoptosis after their
efficacy testing. Our method reduces the procedure and gives information on both aspects in one
assay.
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In this thesis, we divide our report into 4 chapters, beginning with chapter 1: introduction to give
an overview of our research. Chapter 2: Literature review provides background information on
our assay development and the logic behind assay assembly. After the fundamental knowledge
has been laid down we describe the method and the outcome of our assay development in
Chapter3: Prototype development. In Chapter 4: Cell-based MMP inhibitor screening assay, the
result from prototype development were used to assemble our assay and used to examine MMP
inhibitor efficacy in impeding protein breakdown.

For simplicity, readers whom are only interested in the developed assay may over look chapter 3
and begin at Cell-based MMP inhibitor screening assay, Chapter 4, as the methodology, result
and discussion is complete within its own chapter. Readers may only need to refer to chapter 3
for some repeated methods that has already been described in assay development process. Lastly,
the future direction of this research is briefly discussed, Chapter 4.

The findings from our research would provide an alternative method for MMP inhibitor efficacy
evaluation and screening to the conventional zymography technique. By proving the possibility
of slowing down the degradation of protein-based material using MMP inhibitor, it is highly
probable that protein-based implant lifetime prolongation may take place and contribute positive
impact to both medical and scientific community.

3

CHAPTER 2: LITERATURE REVIEW
1. Introduction
In this research we develop a cell based assay prototype for screening potential drugs that may
slow degradation of the protein based materials. For better understanding of our assay, the
literature review presents the background knowledge necessary for understanding our prototype
development. The sections within this chapter include:
1. Introduction
2. Implantable biomaterials
3. Mechanism of degradation
4. Conventional method and the comparison to our developed prototype
5. Experiment design and rationale
5.1. Overview
5.2. DQ-gelatin
5.3. Cell type
5.4. Selected MMP inhibitor: TIMP-1 and BB-94
5.5. Cell adhesion support scaffold
5.6. Cell viability testing
6. Experiment setting
7. Conclusion
We first we describe protein-based materials and their retention time in vivo, section 1. Because
of the benefit in their lifetime prolongation, our research group looks into the mechanism of
biomaterial degradation, section 2, to design our assay based on the events that take place in vivo
after implantation. After that, we introduce the conventional technique used to study MMP
4

proteolytic activity, section 3, then compare with our developed prototype. In Experiment design
and rationale, section 4, we describe a rough picture of our prototype, its each component and
the logic behind the design. Finally, we summarize our research; how each component is
combined to form our assay, outlining our hypothesis and approach, section 5.
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2. Implantable Biomaterials
When minor laceration occurs, a wound healing mechanism is activated and a proper repair of
the laceration take place. But once considerable injury where natural regeneration is not
sufficient happens, biomedical associated technology is required to aid the restoration process.
Because human regenerative capacity is limited, wrinkles form, organs start to malfunction as
people age, scarring and loss of tissue function takes place after severe trauma. To heal these
impairments myriads of biomimetic materials are specifically tailored to provide proper 3dimentional micro-environment and stimulants for cell migration, proliferation, differentiation
and cell organization to form new tissue at the wounded site [20-22]. The materials are also
engineered to be biocompatible, facilitates transport of nutrients and metabolic waste while
having similar mechanical properties to its surroundings, and be able to be remodeled and
replaced at a simultaneous rate with neo-tissue formation. These materials have been intensively
researched since before 2003 [23].

While biomimetic implants are utilized in many types of tissue repair including bone [5],
cartilage [6], nerve [7] and cardiac muscle [8], some are used as space filling agents in the cases
of glottal insufficiency [9, 10], urinary bladder incontinence [11] and for rhytide alleviation in
cosmetic field [1]. These materials are called fillers after their function. Others are utilized in
wound healing stimulations. Because materials with low immunogenicity that hold similar
mechanical property to its surrounding tissue are generally natural, they are degraded overtime
after implant making their satisfactory effect are not permanent.
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Fillers and injectables such as autologous fat have been known since 1893 [24]. It initially was a
very appealing as it posts no immunological threats, is easy to harvest with numerous accessible
donor sites and remains for over one year [25]. But due to the large volume loss, its popularity
has steeply declined. Hyaluronic acid (HA) is one valuable implantable material. They are
secreted interstitial molecules by variety of cells lineage to maintain tissue viscosity and shock
absorbance [26] and are crucial in joints and voice production, rendering them preferable for
vocal fold augmentation [27-31]. Despite their benefits of viscoelastic property, zero
immunogenicity [32], wound healing stimulation [33] and well established safety and efficacy
profile [34], HA’s major drawback is its short-lived nature. Although crosslinking has been
performed in attempt to lengthen its lifetime, HA could only be maintained for only 12 weeks
[35]. In its natural state, hyaluronic acids have been reported to last less than 2 days
subcutaneous [36] and 3-5 days inside vocal fold [37].

Extracellular matrixes (ECM) are cell-secreted mixture of interwoven fibrous proteins and
glycosaminoglycans [38-40], containing small amount of cytokines and growth factors that
modulates cell behavior [41]. They play a major role in wound healing [42] by stimulating
angiogenesis, host cells recruitment, adhesion, proliferation, and remodeling of damaged tissue
[43]. ECM based material can recapitulate natural conditions in vivo [44]. Numerous
publications have confirmed ECM potential in tissue reconstruction [41] including skin, tissue,
vessel, tendon and lower urinary tract. Consequently, ECM represent nature’s scaffold for tissue
repair although their ability to establish complete restoration may be in question since ECM are
rapidly degraded after implant [2, 3].
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Collagen is the most abundant protein in the ECM as well as in human body [45, 46]. It is a
natural constituent of connective tissue and the primary structural protein of all our organs [47].
Other than providing mechanical support and acting as a reservoir of hormones and growth
factor, it plays pivotal role in wound healing process [48]. As implantable material, collagen is
the single substance filler most intensively used and has been manufactured in USA since 1977.
It has received FDA approval and has become the gold standard used to compare engineered
materials for soft tissue augmentation of later generations [49]. Over the years, various collagen
based injectables have been developed and commercialized with different compositions and
wide-range of residential time in vivo [1, 50-52]. None the less, like other natural materials, all
forms of collagen correction are temporary and require periodic maintenance [1, 4].

In short, because of the advantages of implantable protein based materials, both in regeneration
stimulation and as volume fillers for treatment, they are utilized in a wide range of applications
and cause large impact on biomedical industry. Regrettably, the main drawbacks of protein based
implants are their short lived nature; thus lifetime prolongation of these materials would be a
vital next step to enhancing therapeutic effects of biomimetic materials.

8

3. Mechanism of Degradation
By being able to prolong protein based implant lifetime, their therapeutic efficacy would
increase, providing many benefits in both the society and the scientific community. For tissue
regenerative implants such as ECM-based materials, their stimulatory effect of would be
extended, granting better tissue restoration outcome. For filler type materials, its volume may be
retained for longer period, thus, widening gaps between each treatment for people who suffer
glottal insufficiency, urinary bladder incontinence or requiring cosmetic surgery. Therefore,
patients would be provided with more comforts and may lessen their treatment cost in the long
run.

To prolong the lifetime of the implant, it is imperative to acknowledge the mechanism of
material break down. In general, there are 2 different ways that materials are degraded in vivo;
by hydrolysis and enzymatic digestion [53]. The decomposition of polymer-based implant is
largely governed by hydrolysis [54], which could easily be controlled by adjusting their chemical
composition [55]. Our main focus lies on the degradation of protein based materials, where the
decomposition rate cannot be straightforwardly predicted.

Unlike those of polymer-based, the residence time in vivo of protein-based implant is
predominated by their host response they elicit. As protein decomposition is tightly regulated by
cell secreted proteases and is concentrated at cell periphery [56], the higher the material
immunogenicity, the larger cell number are recruited to the implant site, the more concentrated

9

the secreted protease per area. If the implant is susceptible to cellular infiltration and is prone to
enzymatic attack [12] its retention time in vivo is difficult to be prolonged.
From tissue regeneration point of view, the implant site is similar to an injury with
subcutaneously embedded foreign body under the skin lesion. The act of incision is enough to
trigger wound healing, a specific biological process comprise of 5 overlapping independent
stages to reestablish the integrity of the damage tissue [57, 58]. The progression through
hemostasis, inflammation, proliferation and remodeling stages make up the wound healing
sequence [59-61].

Normal healing response take place as soon as tissue is injured [62]. For instance, during a
surgery where bleeding takes place, hemostasis is activated and blood clot forms, sending out
chemotactic cues to recruit inflammatory cells such as monocytes and neutrophils to the implant
cite for pathogen elimination purposes [63]. The immunogenicity determines the extent of
inflammation. Because the degradation is brought about by both resident and infiltrated cells
[12], the material porosity influences its degradation rate. Other than surrogating for pathogens,
neutrophils and macrophages also functions similar to platelets in fibrin clot signaling for
fibroblast and endothelial cells [64]. They gather at the periwound area, infiltrate the clot,
proliferate, undergo angiogenesis, lay down extracellular matrix and form new tissue [65]. The
newly synthesized tissue or the scar tissue is not as strong as the original. The strength of scar
tissue is approximately only 25% of a normal tissue. After several months its mechanical
property can be improved by collagen fibers reorganization and cross linking by the fibroblast
but it will never regain to its native strength. [66]
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The removal of exogenous implants is similar to the regular process of extracellular matrix
(ECM) remodeling [12]. Various types of enzymes are secreted by cells within the immediate
proximity and digest their specific substrates [67]. The well-known ones are the matrix
metalloproteinases (MMPs) for their involvement with wound healing and normal tissue
regulation [13]. They are grouped according to their substrates and are critical to the repair
processes for eliminating necrotic tissue, fibrin clot that forms after bleeding and are also
necessary in cell migration during inflammatory phase [68]. Table 1 summarizes MMPs, their
specific substrates and cellular sources [12, 68].

Protein-based implants can be degraded by a diversity of proteases. To mimic the main
composition of mammalian tissue [69, 70], many of those implants contain collagen. Fibrillar
collagens function to provide mechanical strength and protect the cells they surround, therefore,
it is not easily degraded and is resistant to most enzymatic attacks. Collagenase (MMP-1, 8 and
13) are the specific MMPs with the ability to cleave collagen in their triple helical domain. After
the cleavage, collagen denature into gelatin at physiological temperature and is susceptible to
further digestion by numerous enzymes (MMP-1-3, 7-12, 14, 16-19) including gelatinases
(MMP-2 and 9) [71], making it the easier step in matrix (granulation tissue) remodeling [72].
After it is reduced to amino acid, it can be resorbed and re-utilized in cellular protein synthesis.

Because degradation of implant is modulated by cell secreted MMPs, we believe that by
inhibiting the activity of MMPs, the implant lifetime could be prolonged. Our objective is to
develop an assay that can detect and evaluate substances capable of inhibiting MMP’s
11

proteolytic activity. These substances are referred to as the MMP inhibitors (MMPis). Our
developed assay is a cell-based assay to resemble the phenomena of protein-based implant
degradation in vivo and to investigate the effect of MMPi on cell viability.
Table 1 Matrix metalloproteinase and their substrate
Enzymes
Collagenases
Collagenase-1 (MMP-1)

Collagenase-2 (MMP-8)
Collagenase-3 (MMP-13)

Gelatinases
Gelatinase A, 72 kDa (MMP2)

Gelatinase B, 92 kDa (MMP9)

Stromelysins
Stromelysin-1 (MMP-3)

Stromelysin-2 (MMP-10)
Stromelysin-3 (MMP-11)
Matrilysin (MMP-7)
Metalloelastase (MMP-12)

Membrane-type MMPs
MT1-MMP (MMP-14)
MT2-MMP (MMP-15)
MT3-MMP (MMP-16)
MT4-MMP (MMP-17)
MT5-MMP (MMP-24)

Substrates
Collagen I, II, III, VII, VIII, X, gelatin, aggrecan, versican,
proteoglycan link protein, L-selectin, entactin, tenascin, serpins,
α2- macroglobulin, TNF precursor, MBP, IGFBP-3
Collagen I, II, III, VII, VIII, X, gelatin, aggrecan, fibronectin,
laminin, serpins, α2-macroglobulin
Collagen I, II, III (II>I or III), IV, IX, X, XIV, gelatin, aggrecan,
perlecan, fibronectin, laminin, tenascin, fibrillin, SPARC, serpins,
PAI
Gelatin, collagen I, IV, V, VII, X, XI, XIV, aggrecan, versican,
proteoglycan link protein, fibronectin, laminin, laminin-5,
tenascin, fibrillin, SPARC, elastin, vitronectin, α2-macroglobulin,
TNF precursor, MBP, IGFBP-3
Gelatin, collagen IV, V, VII, X, XIV, aggrecan, versican, nidogen,
proteoglycan link protein, fibronectin, fibrillin, SPARC,
entactin,elastin, vitronectin, α1-antitrypsin, α2-macroglobulin,
TNF precursor,MBP, angiostatin
Collagen III, IV, V, IX, X, gelatin, versican, nidogen, aggrecan,
perlecan,proteoglycan link protein, fibronectin, laminin, tenascin,
fibrillin, SPARC, entactin, elastin, TNF precursor, MBP, IGFBP-3
Collagen III, IV, V, gelatin, nidogen, aggrecan, proteoglycan link
protein, fibronectin, elastin
α1-proteinase inhibitor; weak activity on aggrecan, fibronectin,
laminin
Collagen IV, gelatin, versican, nidogen, aggrecan, fibronectin,
laminin, tenascin, SPARC, elastin, vitronectin, MBP,angiostatin
Collagen IV, gelatin, nidogen, aggrecan, fibronectin, laminin,
fibrillin, elastin, vitronectin, α1-antitrypsin, TNF precursor,
angiostatin
Collagen I, II, III, gelatin, nidogen, aggrecan, perlecan,
fibronectin, laminin, tenascin, vitronectin, fibrillin
Aggrecan, perlecan, fibronectin, laminin, nidogen, tenascin
gelatin, casein
gelatin, TNF precursor
Not determined
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Other MMPs
MMP-18, MMP-19
Enamelysin (MMP-20)
MMP- 21, 22, 23

Gelatin
Amelogenin
Not determined

***Modified from Vaalamo et al.

By providing information regarding their potency in decreased protein decomposition rate and
whether they may influence cell apoptosis, we believe implant lifetime prolongation is a very
possible advancement in medical and biomaterial field that may eventually propel the society
towards a better living standard.
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4. Conventional Method and the Comparison to Our Developed Prototype
Zymography or substrate zymography is a technique extensively used for studying ECM
degrading enzymes [17], MMPs, the group of enzymes responsible for implant degradation
during wound remodeling phase. Zymography is a simple, sensitive, quantifiable and efficient
approach for proteolytic activity analysis of cell and tissue extracts [19, 73]. It is preferred over
other techniques such as gene expression measurement or immunoassay as most MMPs are
encoded as inactive precursors, zymogens, and those assay are not capable of differentiating
between the active form and inactive form. Zymogens are subject to multiple post-translational
regulations before they become activated in the intercellular space [74, 75].

Zymography was first developed by Gross and Lapière for detecting collagen degradation in
1962. The current widely used “substrate zymography” is the adaptation introduced by Heussen
and Dowdle in 1980 [76]. Because MMPs are overexpressed during tumor invasion, this
technique has gained large recognition in cancer and other research field around the world and
has become a well-accepted conventional method for measuring MMP expression [77].
Zymography has been used in both research and clinical settings. It has been used to discover
[78] and identify new types of enzymes [79] or overexpression of enzymes in multiple forms of
cancer [80-83] and neurological diseases [84], study enzyme inhibitors [85] and identify their
optimal dosage. Zymography is also the key technique for studying proteinases expression and
post-translational modifications regulation [86].
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Zymography visualizes enzymatic activity on the basis of substrate conversion. It is an
electrophoretic method where proteins, particularly enzymes, are separated by size in a reducing
SDS gel co-polymerized with protein substrate of choice. SDS inside the gel causes protein to
denature into its unfolded state, rendering them to be separated without bias of their three
dimensional shape. Upon removal of SDS, the proteins renature and exert proteolytic activity on
the protein gel substrate [18]. The enzyme digestion could be viewed by common protein
staining technique, Coomassie blue staining. After destaining to remove excess dyes, the
proteolytic area will appear as white bands blue background of protein gel substrate. Within a
certain linear range, the intensity of the band can be used to quantify the amount of protein
associate with its activity. [17, 18]

Over the past 50 years, more than 20 variants of zymography have emerged to improve specific
aspects according to different research objectives [88]. The most relevant zymography assays
that may be applied to our research are the substrate zymography, reverse zymography (RZ), and
in situ zymography (ISZ). The latter 2 variants go by similar concept to substrate zymography.
Reverse zymography is used for identification of natural inhibitors such as TIMP which also is a
protein. Both Enzyme and substrate are copolymerized within the gel, after staining process, the
area containing effective inhibitors is recognize as dark bands containing intact substrate against
light background [77, 89].

Although RZ shows the inhibitor potency, it does not provide any information related to cellular
response to the inhibitor. The closest method to defining the actual MMP activity in viable tissue
15

would be in situ zymography. The sample is prepared as a thin section and is brought into
contact with the fluorescence substrate. After incubation, the localization of particular proteolytic
activity towards the substrate from enzyme within the biological slice sample can be viewed.
Identification of the responsible enzymes is carried out by IHC after staining [73, 77, 90]. ISZ is
generally used for to pinpoint enzymatic activity but the enzymatic activity can also be
estimated. This format of zymography is the only variant that gives the net activity of the
enzymes within the sample, not the measure of potential enzymatic activity.

Firstly, quantitation of zymograms remains difficult [19]. The sensitivity of substrate
zymography is largely governed by the staining and destaining process. Overstaining of protein
dyes causes bands with low activity to become invisible against blue zymogram background.
Because estimation of MMPs from sample amount is based on multipoint calibration by
dissolving and diluting standards of different enzymes with known concentration, excessive
destaining may bleach out bands with high activity, negating the differences between light bands,
lowering the sensitivity of enzyme quantification.

Secondly, the MMP activity demonstrated by zymography may not represent their proteolytic
capacity in nature. Most MMPs are secreted in their inactive form, zymogens. They are tightly
regulated and gain proteolytic activity only after specific enzymatic cleavage [91, 92]. During
SDS-gelelectrophoresis in zymography, zymogens are unfolded and its inhibitory peptide is no
longer attached from the catalytic site. After SDS removal, the proteins only partially refold
resulting in active enzymes instead of the naturally inactive zymogens. Furthermore, the activity
16

of

MMPs

is

governed

by

various

inhibitors

[93]

such

as

tissue

inhibitor

of

matrixmettalloproteinase (TIMP) which inhibits MMPs even if the enzymes are in there active
forms. In general, MMP in solution non-covalently forms a complex with their corresponding
TIMP. These complexes dissociate in the presence of SDS [94]. Therefore, electrophoresis step
creates artifacts of increasing enzymatic activity and zymography may not display the actual
proteolytic activity but rather, their possible potential in substrate digestion.

Considering the practicality of MMP inhibitor screening assay, it would useful if the optimal
dosage of each inhibitor could be determined. Because electrophoresis unavoidably increases
enzymatic activity from that of the natural state [86, 95, 96], substrate zymography may not be
the best option. In situ zymography offers advantage over the conventional substrate zymogrphy
in the sense that it somewhat provide insights on the net enzymatic activity in living system. But
both in situ and in gel zymography are time consuming and a large number of experiments needs
to be conducted for testing out different MMP inhibitors and dosages are not suitable for large
scale screenings.

We believe the prototype introduced in this study provides a better alternative for screening
MMP inhibitors capable of prolonging implant lifetime to other conventional methods. As cells
are a living units that response to external stimuli, disruption in ECM remodeling could upregulate MMP expression and leading to excessive ECM degradation. Results from cell-based
assays may simulate degradation of material overtime after implant better than ISZ tissue slice
conducted over short time period [66] or common assay with single or multiple enzyme
17

component where no response from viable components are involved. Adopting 96-well plate
setting, our assay can provide comparative efficacy of different inhibitors at different
concentrations in couple to their effect on cell viability. In this way, it is possible to visualize
optimal dosage with minimal assay runs. Because MMP and their natural inhibitors are relatively
expensive, our assay may even prove to be the more efficient method for inhibitor screening.
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5. Experimental Design and Rationale
5.1. Overview
Our aim is to assemble an assay prototype for screening potential inhibitors capable of slowing
down implants degradation. Because the breakdown of implants takes place in a similar manner
as ECM digestion, modulated by MMP catalyzed hydrolysis, our prototype is designed to test out
the enzyme inhibitors efficacy while ensuring considerable cell apoptosis is not induced. As the
first step towards in vivo testing, this assay is designed and resembles the physiological
phenomena that take place around the implant while remain practical and easy to use. Cells are
cultured in the presence of fluorescence labelled substrate that emits signals proportional to the
extent of its degradation. The inhibitor of choice is added to the culture in a varied amount. The
experiment is constructed to give the inhibition efficacy in terms of percentage of the
fluorescence intensity given out by the control where MMP inhibitor is not introduced into the
cell culture vessel. The distinctive of the signal from background, signal-to-noise ratio, from this
assay is optimized by varying number of seeded cells, substrate concentration, reaction time and
experiment setting, having or not having cell adhesion scaffold. Cell viability assay is conducted
after experiments to estimate how many cells still remain alive after the assay run time.

In this chapter, we describe the rationale behind the assay design; the fluorescence substrate, cell
type selection, MMP inhibitor, and the detail of experiment planning and signal optimization in a
separate section below.
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5.2. DQ-Gelatin
In our assay, a fluorescent signal is used as our means of degradation detection. Cells are
cultured in presence of the material representing natural implants, DQ-gelatin. DQ-gelatin is a
commercially available gelatin heavily labelled with Fluorescein isothiocyanate (FITC) that
emits fluorescence proportional to its own extent of degradation.

In general, the occurrence of fluorescence takes place through relaxation of fluorophores from
excited states to its original ground state emitting photons light signals [97]. In DQ-gelatin, the
gelatin conjugated FITC are located in such close proximity that one molecule interferes with
fluorescence of another, resulting in fluorescence quenching when DQ-gelatin is in its intact
state. Once cleaved by gelatinolytic activity, the distance between those fluorophores increases,
enabling fluorescence to take place after the conjugated FITC are excited, giving fluorescence
emission against weakly fluorescence background [73].

Enzyme

Self-quench substrate

Fluorescent product

Figure 1 Fluorescence emission in DQ-gelatin. Fluorophores in close proximity interferes with
fluorescence activity of one another. Once cleaved, self-quenching effect is dwindled resulting in
fluorescence emission upon excitation of the fluorophores.
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DQ-gelatin has been used in various MMP related research where cells are cultured in its
presence over a prolonged period [98, 99]. From those studies, many studies apply DQ-gelatin in
solution form, many as cell substrate such as for in situ zymography to locate proteolytic activity
or to measure the efficacy of the enzymes or in some cases, both. From these experiments we
assume that DQ-gelatin displays low-toxicity towards living cells in culture. The dye quench
DQ-gelatin provides a higher sensitivity than normal fluorescence conjugation and also serves as
a good substrate since gelatin can be digested by not only gelatinases but by a large repertoire of
enzymes (Table1). Concisely, this commercialized product is selected to portray protein based
implants for its similarity to natural gelatin, adequate biocompatibility, as a substrate specific to
many groups of MMP and high sensitivity in signal generation proportional to gelatinolytic
activity.

5.3. Cell Type
During cellular infiltration of implant in the inflammatory phase, immune cells are recruited to
the wounded site along with fibroblast. The Macrophages and neutrophils clears out pathogen,
their number increases depending on the implants immunogenicity while fibroblasts migrate to
site for regenerative purpose. They are responsible for both closing up the open laceration and
repair tissue injury to the very last stage. Their number increases until they predominate the area.
At the wound edge fibroblasts gather and differentiate into myofibroblasts stimulating
contraction and wound closure [100]. To restore structure and function to the damaged tissue,
fibroblasts produce new matrix such as collagen, elastin and proteoglycan along with degrading
provisional one. Fibroblasts are the major source of MMPs that degrades extracellular matrix
[101]. These MMPs are capable of digesting entire extracellular matrix components [102, 103].
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Accordingly, all constituents of exogenous implant that are substrate specific to the secreted
MMPs will be degraded along with ECM as a part of the regeneration process. If implants does
not cause prolonged detrimental inflammation, the principle cell type that interacts with it is
most probably the fibroblasts.

In order to develop a prototype that resembles the physiological condition and keep the assay
practical, fibroblast is the only one cell type used. They perform important function in wound
healing, are widely utilized in research, are commercially available, and are relatively easy to
purchase and maintain. The cell line utilized in this research is the standard fibroblast cell line,
NIH-3T3, a cell line established since 1962 from Swiss albino mouse embryo tissue [104]. It is
very robust, stable and it is relatively easy to culture in vitro. From our consideration, it is the
suitable cell line to be incorporated into our research in order to assemble a practical assay for
proteinase inhibitor screening.

5.4. Cell Adhesion Support Scaffold
In this experiment, we focus on the fluorescence intensity resulting from cleavage of DQ-gelatin
by viable cell secreted MMPs. Under normal physiological conditions, the level of MMP
expression is very low, both in vivo and in cell culture [105]. Therefore, high concentration of
cells is required to generate adequate amount of secreted MMP in order to achieve acceptable
fluorescence signal emission. Fibroblasts, NIH-3T3, are anchorage dependent cells that grow in
monolayer in culture. They require appropriate substrate for cell adhesion to survive [106]. By
introducing porous cell anchorage substrate, we may provide more surfaces for NIH-3T3 and
increase the viable cell number measured at the end of experiment.
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Figure 2 Cryosliced fabricated polymer scaffold, scale bar = 100 µm.

Our research group utilizes porous polymer scaffold as cell adhesion substrate in many projects
[107]. The low cost and simple to fabrication scaffold is prepared by pouring aqueous free
polyether-based thermoplastic polyurethanes (TPUs) solution into soft rubber mold filled with
sugar. The solution seeps through space between sugar grain and fills the mold, creating porous
structure once the sugar is dissolved out by water rinses. Data generated from analysis of the
fabricated cryosectioned scaffold shows 67.31±8.84% pore area with very uniform density
59.08± 4.84 µg/mm3, indicating very uniform results when compared between each scaffolds.

From Figure2 high surface area could be observed, by comparing the dimension of pore size on
the scaffold and NIH-3T3 cell, approximately 50 – 80 µm, pore size is wide enough for 3T3 to
grow between the connected empty spaces. Therefore, the developed porous structure within the
scaffold creates larger surface within the same experimental volume providing more area for
fibroblast to adhere, thus are able to increase the number of viable cells remaining after
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experiment. Despite the attractive potential, addition of scaffold into our assay makes the assay
preparation process more complicated. During assay development, we have also conducted
experiments to observe whether NIH-3T3 could be maintained without scaffold. The
experiments were prepared to have one set containing scaffold and the other not containing
scaffold to see the comparison. MTT assay was performed to confirm cell viability after these
experiments.

5.5. MMP Inhibitor TIMP-1 and BB-94
Degradation of protein-based implant is modulated by the same process of (granulation tissue)
ECM remodeling, MMPs-catalyzed hydrolysis. Matrix metalloproteinases or MMPs are a family
of structurally related zinc-dependent enzyme, collectively capable of digesting all components
of ECM [14, 15]. The natural inhibitor of MMPs includes the tissue inhibitors of
metalloproteinases (TIMPs), α1-proteinase inhibitor and α2-macroglobulin. TIMPs are the major
endogenous MMP inhibitor in tissue. They maintain the balance between ECM deposition and
degradation in physiological and biological process [16]. TIMP bind to highly conserved active
zinc-binding sit of MMPs at molar equivalence and suppress proteolytic activity. So far, 4
members of the TIMP family has been characterized; TIMP-1, TIMP-2, TIMP-3 and TIMP-4.
Although different TIMPs bind to different MMPs with different affinity, both TIMP-1 and
TIMP-2 are capable of inhibiting all known MMPs [16]. While in general TIMP plays inhibitory
role, at low concentration, TIMP-2 enhances the activation of MMP-2, there by raises proteolytic
activity.
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In a healthy tissue, TIMP concentration normally far exceeds MMP concentration, limiting
proteolytic activity to only focal pericellular sites. Although the situation of TIMP and MMP
expression in injured tissue is complicated and not fully understood [68], the activity of MMP is
critical in wound healing. MMP is required for debridement, cut through fibrin clot and
remodeling (granulation tissue) ECM once those migrated cells populates the wounded area. As
an example, collagenase activity has been shown to quickly be induced and up-regulated at the
wound edge [108], during cellular infiltration of fibrin clot [72], persist during wound healing
and cease after the end of re-epithelialization [109]. Different MMPs is expressed and regulated
differently during these events [102].

As MMP expressions are elevated in most human tumors [110], MMP has been held as
promising target for cancer therapy for over 30 years [111]. So far, large number of drugs
targeting MMP has been developed to impede metastasis and angiogenesis during tumor
invasion [112]. Many drugs have shown compelling results in animal studies [111];
unfortunately, most fail later during human clinical trials [110,113,114]. One of the major
postulated reason issues is that the synthesized MMP inhibitors are broad-spectrum chelator,
incapable of discriminating between different zinc-dependent proteases. Because our aim is not
to identify the best MMP inhibitor but to assemble an assay capable of discerning MMPi
potency, therefore, the only requirement for selecting our test inhibitors would be that they do
not cause cells apoptosis. BB-94 is one of those synthesized MMP inhibitors that has many
successful cases in animal studies [115-118] and is the first MMPi tested in Phase I studies
[119]. The clinical trial has continued to Phase II in Europe [120] but Phase III has been
discontinued because of slow patient accrual [121]. Because of its many successful cases in vivo,
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it is chosen as our test MMP inhibitor along with TIMP-1 that has the inhibition spectrum over
all known MMPs. And by introducing MMP inhibitors, we hypothesize that the extent of
proteolysis of DQ-gelatin in our assay will be reduced.

The selected range to test out MMP inhibitors for our experiment is based on the estimate value
of the MMP expression level in tissue, and the IC50 value which indicates drug’s effectiveness.
In normal wound, the approximate collagenase expression is 0.1-1.3 µg/mL of wound fluid with
the average of 87 µg/mL. Because TIMP-1 binds to MMP at molar equivalence and that TIMP-1
is a costly reagent, our test range is 0.1-2 µg/mL. BB-94, or batimastat, is a potent broad
spectrum MMP inhibitor which under physiological condition inhibits MMP with IC50 value in
nM range; MMP-1(3 nM), MMP-2 (4 nM), MMP-3 (20 nM), MMP-8 (10 nM) [119, 123] and
MMP-9 (10 NM) [123]. According to FDA, IC50 is the drug concentration require for 50%
inhibition of specific biological process in vitro. Therefore, our test range for BB-94 is 20-1000
nM.

5.6. Cell Viability Testing
To imitate implant degradation in vivo, the signal that we are interested in is the signal produced
by viable cells. Therefore, it is imperative to verify the estimates of how many cells remain
viable throughout the assay. The determination of viable cell number is use in many types of
research such as drug testing, cytotoxicity test and biologically active compound screening. One
of the most versatile assays commonly used these days is the MTT assay [124]. It involves the
conversion of the main assay component (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide) or MTT by mitochondrial dehydrogenases of viable cells [125-127]. The enzyme
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cleaves the tetrazolium ring, transforming yellow soluble MTT into purple insoluble formazan
crystals which dissolves in acidified isopropanol and the purple solution may then be measured
spectrophotometrically using plate reader set to read absorbance at wavelength 570 nm. The
higher the optical density, the higher the viable cell number counts. By preparing standards with
known number of viable cells the information from absorption data can be interpreted.

As this simple, yet accurate method is performed as the last step our MMP inhibitor screening
assay to ensure the estimate number of viable cells are at acceptable level. Our assay is set to
optimize MTT test measurements and avoid components that interfere with the process. MTT
assay yields highly sensitive result at cell concentration up to 106 cells/100 µL media. The
sensitivity may lower with the increment of cell number, high protein concentration, presence of
phenol red and extended incubation time of MTT with viable cells [128]. Therefore, the growth
media in our assay uses phenol red free DMEM/F-12 media instead of regular formulation,
exclude addition of FBS and the cell viability testing is conducted outside this process is conduct
outside the original 96-well experimental vessel with the incubation time of 4 hours.
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6. Experiment Setting
Our assay takes place in 96-well plate setting. The total reaction volume of 200 µL in our
experiment may consist of DQ-gelatin solution dissolved in buffered fibroblast growth media,
fibroblast and MMP inhibitor of choice. Signal optimization process is performed to achieve the
highest signal-to-noise ratio while retaining high NIH-3T3 viability (detail discussion is reported
in Chapter 3). We assume that, under optimized condition, the effect of inhibitor will be most
pronounced. From previous experiments (data not shown) evaporation tremendously affected
fluorescence measurement. Therefore, the outer most rows are not used as experimental vessels
but are filled with sterile filtered DI water to reduce the evaporation of other inner wells of the
96-well plate. Fluorescence emission increases as DQ-gelatin is broken down and is used as
indicator of gelatin degradation. The more potent the inhibitor, the less fluorescence is generated.

In general, a reliable assay generates a strong signal as a result of the target reaction occurrence.
Thus, Signal optimization process is performed to achieve most distinctive fluorescence signal
possible compared to emitted background while retaining high NIH-3T3 viability. The
concentration of DQ-gelatin and fibroblast were varied to see the best concentration that produce
highest signal-to-noise ratio. The experiments were conducted in 2 different settings; one having
the cell adhesion support scaffold while the others don’t, in order to examine whether the
scaffold is a required component in the assay.

After the optimal condition to generate considerable fluorescence emission while retain high
NIH-3T3 viability is obtained, It is used to assemble our cell based assay and test out MMP
inhibitor efficacy. MMP inhibitor is only used after the assay has fully been developed.
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7. Conclusion
Now a day, a large variety of protein-based biomimetic material has been used in a wide range of
applications [129]. Despite their great potential, after implant majority of those materials
degrades at a faster rate than the body could regeneration. Thus, lifetime prolongation of protein
based materials may be a practical way to improve the implants therapeutic efficacy. In general,
degradation of protein based implants take place in a similar manner as ECM remodeling, which
is by MMP catalyzed hydrolysis. By inhibiting proteolysis activity of these MMPs, the implant
retention time under physiological condition may be extended.

The purpose of this research is to assemble a cell-based MMP inhibitor screening assay
prototype that resembles protein-based implant breakdown in vivo. As the dominant cell type at
implant site, fibroblast is selected to be used as MMP source. It is cultured in presence of DQgelatin, a heavily fluorescence labelled gelatin that gives off fluorescence emission proportional
to the extent of its degradation. To investigate the effect of MMP inhibitor, the substance is
introduced into the culture containing fibroblast and DQ-gelatin. After specific period, the
emitted fluorescence signal is measured. The efficacy of the MMP inhibitor is obtained by
comparing how much signal is reduced as the result of MMPi addition.

Living tissue compose of viable cells, therefore in our assay, high cell viability must be
maintained throughout the testing period. Because fibroblasts require substrates to survive and
normally grow in monolayer in vitro, cell adhesion support scaffold is included into our assay.
Cell viability test is conduct after every fluorescence-signal measurement to ensure fibroblasts
are still viable after specified period.
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Hypothesis: We believe that our assay could detect the inhibitory effect of MMPi on viable cell
modulated protein degradation.

Approach: Fibroblast, NIH-3T3, is cultured in presence of DQ-gelatin which emits fluorescence
corresponding to how much it has been broken down. The efficacy of MMP inhibitor is
determined from how much fluorescence signal reduction take place as a result of that inhibitor.
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CHAPTER 3: NOVEL ASSAY DEVELOPMENT
1. Rationale
Our aim is to assemble a cell-based assay capable of evaluating MMPi efficacy on delaying rate
of proteolysis. As our assay is designed to mimic the degradation of protein-based materials after
implant, the signal of our interest is the fluorescence signal generated from breakdown of DQgelatin by living cells thus; NIH-3T3 must remain viable after signal measurement. In this stage
of novel assay, there are 3 main aspects of concern (1) the difference in level of generated signal
from background fluorescence (2) cell viability and (3) practicality of the assay. An assay and
produce high signal-to-noise ratio generated from cellular activity of viable cells that is easy to
assemble is most desired.

It has been reported that cells in unstimulated culture express low level of MMP [105], therefore,
high number of cells may be required to generate significantly distinct signal from the
background. But as more cells are inserted into experimental vessel, less area is available for
cells to adhere and nutrients are consumed within shorter period, assay optimization process is
necessary to identify highest seeded cell number that could be seeded and maintained until the
assay is complete. DQ-gelatin concentration and experiment time is also varied to find the best
condition that gives the most recognizable signal against background fluorescence.

We have considered looking into stimulating MMP production of fibroblast in culture. Although
MMP expressions can be induced by various exogenous signal such as cytokines and growth
factors [105, 130], specific substance up-regulate specific MMPs, e.g. IL-1, EGF, and bFGF
stimulates the production of MMP-1 and MMP-3 [130, 131] and each MMP has different
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activity towards different substrate and may induce other cellular responses that are not associate
with proteolysis. We have not found a substance to stimulate MMP production without changing
cellular response in other aspects. Thus the act of MMP production induction itself creates the
artifact. Therefore, our best option remains only to vary those conditions mentioned above,
namely; the seeded cell number, fluorescence-substrate concentration and incubation time.

Fibroblasts are anchorage dependent cells; by providing less than adequate surface area for cell
adhesion, those fibroblasts may undergo apoptosis before the end of experimental process. For
this reason, scaffold for cell anchorage is introduced into our prototype. We are aware that by
having scaffold as a component we reduce the practicality of our assay preparation, despite the
ease of fabrication and economical production cost. To prove the scaffold necessity, experiments
for signal optimization were conducted in 2 settings; a) without scaffold and b) with scaffold.
After each fluorescence measurement, MTT cell viability assay was conducted to determine the
number of viable cells.

The optimal condition we aim to identify is the condition most convenient to prepare, generate
most dissernable signal while retaining the majority of NIH-3T3 population. Because
optimization of one desired aspect may post negative effect on others, each factor effecting
signal-to-noise ratio, cell viability and the practicality of the assay as important correlating
factors that cannot be considered separately. Assay optimization process must be done to
investigate the signal trend caused by different factors and the most appropriate condition to use
in order to assemble or cell-based MMP inhibitor screening assay.
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2. Methodology
2.1. Cell Adhesion Support Scaffold
The porous scaffold for cell adhesion support was fabricated by pouring polyurethane solution
into sugar filled soft silicon rubber mold. The size of each scaffold was based on the dimension
of each well in 96-well plate. To prepare the rubber mold, 3/16” hole was punched into 1/8”
thick soft silicone rubber sheet (McMaster-Carr) using hole-puncher. Moist sugar was prepared
by mixing 10g of sugar with 200 µL of deionized water. The sugar was pressed into the rubber
mold and placed in 75°C oven to dry. Polyurethane solution was prepared by mixing 1 gram of
Tecoflex SG80-A (Thermedics) per 10 mL of dimethylacetamide, DMAc (Alfa Aesar), in round
bottom flask. The mixture was placed on hot plate to dissolve; the temperature was set to
approximately 60 °C with 400 rpm stirring. Once the polyurethane was dissolved, it was poured
drop-wise onto the sugar filled rubber mold. Dry sugar was sprinkled over the mold to remove
excess polyurethane solution then the sugar was leveled at the brim of the mold by shaving off
sugar outside the 3/16” cavity. The mold was carefully placed into container filled with
deionized water and was left overnight to dissolve out sugar forming porous polyurethane
scaffold. The scaffolds were thoroughly rinsed by constantly stirring scaffold in deionized water
for 12 hours. Rinsing was repeated 3 times to ensure removal of cytotoxic DMAc. The scaffold
was placed in 75% ethanol for sterilization and was washed in DPBS (Gibco) 3 times before
coating with 20 µg fibronectin (Gibco) per 1 mL sterile filtered deionized water overnight to
facilitate cell adhesion.
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2.2. Cell Culture and Propagation of NIH-3T3
Cryopreserved NIH-3T3 (ATCC) were thawed, transferred to 15 mL centrifuge tube (VWR),
added with 10 mL of DMEM/F12 media (Gibco) and centrifuged at 300 rpm for 5 minutes. The
supernatant was aspirate to remove DMSO from the cryopreservation media. Cell pellets were
suspended in fibroblast growth media (DMEM/F12 media (Gibco) supplemented with 10% fetal
bovine serum (Gibco), 1% glutaMAX (Gibco) and 25 µg/mL gentamicin (Gibco)) and
transferred to T-75 tissue culture flask (VWR). NIH-3T3s were maintained under standard
condition (5% CO2, 95% humidity at 37°C). When reach confluence, NIH-3T3s were treated
with 0.25% trypsin-EDTA (Gibco). Trypsinization was stopped by addition of growth media,
centrifuged and resuspended. Cells were expanded using 3-6 split ratio for each passage until the
desired number of cells was obtained. All procedure were carried out under strict aseptic
conditions.

2.3. Signal Optimization
Signal optimization experiments took place in tissue culture treated black 96-well plate (VWR).
The total reaction volume of 200 µL in the experiment may consist of DQ-gelatin solution
dissolved in buffered fibroblast growth media, fibroblast and MMP inhibitor of choice. 10X
reaction buffer was prepared using sterile filtered 0.5 M Tris-HCl, 1.5 M NaCl and 50 mM
CaCl2. 1X reaction buffer is prepared by combining growth media, which compose of phenol red
free DMEM/F12 (Gibco) supplemented with 1% glutaMAX (Gibco) and 25 µg/mL gentamicin
(Gibco), with 10X reaction buffer in 9:1 ratio and was used for diluting DQ-gelatin and cell
suspension. NIH-3T3 were treated with 0.25% trypsin-EDTA (Gibco) for cell detachment then
stopped with growth medium. Cell suspension was centrifuged at 300g for 5 minutes. The
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supernatant were aspirate out and the cell pellets were re-suspended in reaction buffer into high
concentration cell suspension ready for seeding. In this signal optimization process, 2 sets of
similar experiments are conduct; setting a) using scaffold and setting b) not using scaffold.

2.3.1. Setting a)
In setting a) Cells were seeded into 96-well plates at 0.002, 0.0042, 0.014, 0.035, 0.1, 0.4, 0.8
and 1.2 million cells per well. All wells were used except the outer most rows. DQ-gelatin was
dissolved in reaction buffer and transfer to 96-well plate to have final concentration of 5, 10, 25
and 50 µg/mL. The total reaction volume in each well is 200 µL. Each condition was prepared in
triplicated. This preparation is repeated in four 96-well plates for four time-points measurement.
After the four plates were prepared and the outer most rows is filled with sterile filtered
deionized water, they were wrapped in tin foil to prevent light exposure. The plates were
transferred into incubator and kept under standard tissue culture conditions for 3, 7, 10 and 15
hours. At the designate time, the emitted signal is read using plate reader set to read florescence
with absorption maxima approximately at 495 nm and emission maxima approximately at 515
nm.

2.3.2. Setting b)
In setting b) the experiment were conducted in similar manner with setting a) with a few
exceptions that cells adhesion support scaffold were used. The 2 fibronectin coated scaffolds
were placed in each well of 96-well plate and aspirate dried. NIH-3T3 were seeded at 0.1, 0.2,
0.4 and 0.8 million cells per well and the preparation is repeated in three plates for three timepoints measurement after 1, 3 and 5 days.
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2.4. NIH-3T3 Viability Testing
After every fluorescence measurement, the percent viability of NIH-3T3 for each condition was
quantified by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay
utilizing the conversion of yellow MTT to purple formazan by active mitochondrial
dehydrogenase in viable cells according to the manufacturer protocol (Sigma) with minor
modifications. Briefly, standard with known cell number was prepared and transferred separately
to 24-well plate along with all content from each well in 96-well plate. 100 µL of 12 mM MTT
solution, prepared by dissolving MTT in sterile DPBS (invitrogen), was inserted to each well
follow by 700 µL of DMEM/F12 without phenol red. The plate was incubated at 37°C for 4
hours, then 1 mL of formazan dissolving solution, 0.1 N HCI dissolved with 10% Triton-100 in
anhydrous isopropanol, was added to each well and mix thoroughly to solubilize formazan. The
absorbance of the purple formazan solution was measure by plate reader at wavelength 570 nm.
Viable cell number was estimated using prepared standard curve.

2.5. Mathematical Model Construction and Statistical Analysis
Numerical data for fluorescence signal and MTT viability assay were assessed by JMP Pro11/
statistical analysis package. Data were compiled to visualize how DQ-gelatin concentration,
seeded cell number and reaction run-time effect the signal-to-noise ratio and cell viability.
Mathematical model were constructed based on those data to find the optimal condition to
achieve distinct signal while fibroblasts still remain viable.
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As for statistical analysis, ANOVA was performed to determine statistical significance between
groups, i.e. inhibitor or concentration, followed by Tukey test once significant difference was
detected. Statistical significance was considered at p values of less than 0.05.
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3. Result and Discussion
To find the specific condition that would produce highest signal-to-noise ratio while maintaining
high cell viability, assay optimization process was conducted. The experiments were prepared in
two settings; setting a) without scaffold and setting b) with scaffold. Seeded cell number, DQgelatin concentration and incubation time were varied. At designate time, florescence was
measured and MTT assay was performed to estimate cell viability. The emitted fluorescence is
converted into signal-to-noise ratio to signify how different the cell-related emitted signals are
from the background fluorescence. Absorbance from MTT assay was converted to cell number
estimates based on the known prepared standards. The signal-to-noise ratio and NIH-3T3
viability were combined and assessed using JMP pro11 formed into mathematical model to
obtain optimal condition that generate high signal-to-noise ratio while keeping the cells alive.
From the generated model and statistical analysis, the factors and their significance on signal-tonoise ratio and cell viability could be illustrated.

3.1. Setting a)

Figure 3 Analysis of variance. ANOVA of setting a) signal-to-noise ratio in signal optimization
process; treating each specific condition; concentration and cell seeding number as one treatment
(n=3, p<0.05)
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Analysis of variance suggests that there are significant differences resulting from varying
experiment preparation conditions; seeded cell number, DQ-gelatin concentration and incubation
time. From the complied signal-to-noise ratio, mathematical model or prediction plot with R2
value of 0.92 were constructed. In statistical analysis, R2 provides measure of how well the
model represents the data in terms of proportion of total variation of outcomes explained by the
model, ranging from 0-1 [133]. With R2 of regression plot equivalent to 0.92, the ability of the
constructed model to predict real value is relatively very accurate.

Figure 4a Actual by predicted plot. All actual collected signal/noise data are displayed as black
dots against red predicted plot.
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Figure 4b Actual by predicted plot. Signal-to-noise ratio from experiments with seed cell
number between 0.002-0.1 million cells.

Figure 4c Actual by predicted plot. Signal-to-noise ratio from experiments with seed cell of 0.4
million cells.
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Figure 4d Actual by predicted plot. Signal-to-noise ratio from experiments with seed cell
number between 0.8-1.2 million cells.

Figure 4 shows actual signal-to-noise ratio from collected data as round dots plotted against the
established mathematical model displayed in red line. The signal-to-noise ratio of experiments
with seeded cell number equals to 0.002-0.1 million cells, 0.4 million cells and 0.8-1.2 million
cells are presented as black dot on figure 4b), 4c) and 4d) respectively. From the figure, it could
be concluded that as the number of seeded cell increases, the higher signal-to-noise ratio
produced.

The predicted plot or the mathematical model generated from collected signal-to-noise ratio via
JMP consist of 3 experimental variables; seeded cell number, experiment time and DQ-gelatin
concentration. Statistical analysis of the mathematical model (Figure 5) shows the extent of
significance post by each variable term on signal-to-noise ratio generation. Probability values
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shown in orange are highly significant while the values shown in red are significant at 0.05 level.
By far, the number of seeded cell place highest impact on signal-to-noise ratio production. The
terms shown below are used to construct our mathematical model displayed on figure 5. Once
included in the model, terms with higher significance will cause predicted value to be closer to
the collected data, resulting in constructed model with higher R-square value.

To investigate how each experimental variable; seeded cell number, DQ-gelatin concentration
and incubation time, affects the trend of signal-to-noise ratio, the generated data were plotted
against varying value of 2 selected factors in 3 dimensions. In Figure 6a) on horizontal axis are
the seeded cell number and the DQ-gelatin concentration. The signal-to-noise ratio data are
shown as black dots against the green sheet model. The vertical lines of dots are data generated
at the same seeded cell number and DQ-concentration with different incubation time. The higher
signal-to-noise ratio is the shorter the incubation time (data not shown). Similarly, in Figure 6b)
the seeded cell number and incubation time are displayed on horizontal axis. The vertical lines of
dots are signal-to-noise ratio produced by experiments with same seeded cell number and
incubation time but at different DQ-concentration.

The prediction profiler enables a clear visualization of how each experimental variable affects
the trend of signal-to-noise ratio at specific condition. On Figure 6 c), the trend at conditions that
produce the highest signal-to-noise ratio is shown. The shortest incubation time, highest DQgelatin concentration and largest number of seeded cell provides the best/most preferable
condition of signal optimization. The steepness of the trend shows how much change in that

42

variable affects the signal-to-noise ratio. The effect of variation in seeded cell number on signalto-noise ratio is by far greater than that of concentration and incubation time.

Figure 5a Sorted parameter estimates and mathematical equation of constructed model. 9
terms of parameter estimates that are used to generate signal/noise ratio model

Figure 5b Sorted parameter estimates and mathematical equation of constructed model.
The terms are presented orderly with respect to their significance on model-fitting.
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1.162240 + (1.347825 * Seeded Cell # ) + [(-0.850079) * (Seeded Cell # - 0. 281786)2] +
[(-0.0194441) * (Hours - 8.735499) * (Seeded Cell # - 0.281786)] + [(0.003620) *
(Conc - 22.436195) * (Seeded Cell # - 0. 281786)] + ((-0.001693) * Conc) +
[(0.000080) * (Conc - 22. 436195)2] + (0.002814 * hours) + [(-0.000122) *
(Hours – 8.735499) * (Conc - 22.436194)] + [(-0.000302) * (Hours - 8.735499)2]
Intercept + [(1.347825) * 1 ] + [(-0.850079) * 2 ] + [(-0.194441) * 3 ] + [(0.003620) * 4 ]
+ [(-0. 001693)* 5 ] + [ (0.000080) * 6 ] + [(0. 002814) * 7 ] + [(-0.000122) * 8 ]
+ [(-0.000302) * 9 ]

Signal/noise

Figure 5c Sorted parameter estimates and mathematical equation of constructed model.
Mathematical model for signal-to-noise ratio prediction. Term Seeded Cell # refers to seeded cell
number, Hours refer to incubation time and Conc refers to DQ-gelatin concentration

Figure 6a 3-Dimensional plot of signal-to-noise ratio. Signal-to-noise ratio data is plotted
against seeded cell number and DQ-gelatin concentration
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Signal/noise
Figure 6b 3-Dimensional plot of signal-to-noise ratio. Signal-to-noise ratio data is plotted
against seeded cell number and incubation time.

Reaction Time
(hour)

Seeded Cell #
(x106)

DQ-gelatin
(µg/mL)

Figure 6c 3-Dimensional plot of signal-to-noise ratio. Prediction profiler set at the optimal
condition for signal generation.
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After the signal to noise ratio trend has been established, we identify the significant difference
within each variable by performing Tukey test, shown in Figure 7 (n=3, p<0.05). Signal-to-noise
ratio barely increase as incubation time is prolonged and does not linearly vary in according to
DQ-gelatin concentration but significantly escalates as seeded cell number is increased. Despite
the modest value of signal-to-noise ratio, all conditions of seeded cell number produce
significantly distinct signal-to-noise ratio from the no cell control. This result confirms the
reliability of our assay.

In conclusion, the signal-to-noise ratio generated from DQ-gelatin break down is largely
governed by seeded cell number. Their significant influence is supported by the 2-dimensional
plot in Figure 3, parameter estimates in Figure 4, the slope of signal-to-noise ratio trend in figure
6 and from statistical analysis. Signal-to-noise ratio is also affected by DQ-gelatin concentration
and incubation time but in a lesser extent. The result from constructed model may differ a little
from statistical analysis in figure 7. This is because the model shows the prediction at specific
condition, (n=3), e.g., at certain DQ-gelatin concentration, seeded cell number and incubation
time but in Tukey-test, one condition of one vaiable is fixed consequently, the information is the
average of the estimate over a wide range of condtions and the signal-to-noise trend varies as the
governing experimental condition changes. Therefore, if one is interested to predict signal-tonoise ratio or trend at specific condition, it would be more accurate to rely on the constructed
model, figure 6, rather than the overall result separate by certain category presented by Turkey
test, figure 7.
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Seeded Cell # (x106)

DQ-gelatin (µg/mL)

Reaction Time (hour)

Figure 7 Turkey Test analysis on each experimental viariable. Tukey test on incubation time
(n=108), seeded cell number and (n=54), DQ-gelatin concentration (n=108).

Cell Viability Test
After fluorescent signal measurement, MTT cell viabiliy test is performed to estimate the number
of remaining viable cells. Yellow MTT solution is converted to purple formazan crystal via
components of viable cells and is measured by absorption. The approximate number of viable
cell can be obtained from comparing obtained result against a standard curve. The number of
viable cells are translate and presented as percentage of the initial seeded number.

Our aim is to verify usable conditions that generates high signal-to-noise ratio while maintaining
high viable cell percentage. It is not our focus to study how experimental variable excerts impact
on cell viability and proliferation. The produced cell viability percentage used for statistical
analysis and to construct a mathematical model having each experimental variable set as noncorelating factors. The analysis of varience suggest there are significance difference between cell
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viability percentage resulting from different conditions (n=3, p<0.05). The obtained model has
the R2 value of 0.93 showing relatively high accuracy in predicting actual percent viability.

Figure 8a Statistical analysis of cell viability test setting a). Actual data plotted against
predicted model as black dos against red line

Figure 8b Statistical analysis of cell viability test setting a). Anova of setting a) cell viability
test
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Figure 8c Statistical analysis of cell viability test setting a). Parameter estimates, displaying
the significance of parameters on model fitting

Figure 9 gives a rough estimation that cell viability percentage is majorly dictated by the seeded
cell number. The lower the number of cell initially seeded the higher percent viability. The over
100% value in cell viabliliy gives an indication of cell ploriferation. As the number of seeded
cell is increased, the viability percentage drops. The assumtion the the cell viability percentage is
largely affected by seeded cell number is also confirmed by the relatively high F-ratio in
parameter estimates, Figure 8c).
To conclude signal optimization setting a), signal optimization experiment sets without scaffold,
the experiment conditions that generates the our highest range of signal-to-noise ratio could not
maintain a satisfactory level of cell viability while those that are capable of maintaining more
than 80% viability produces less discernible signal. Therefore, although all level of seeded cell
number produce statistically significant distict signal from the background, the conditions that
supports cell viability produce low signal-to-noise ratio and thus we suggest finding another
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alternative that could produce acceptable signal strength while keeping more cells alive

Viability %

throughout the course of experimental procedures.

Seeded Cell # (x106)

a)

Figure 9a NIH-3T3 Cell viability percentage. Cell viability is reported in percent of the
original seeded number. Viability percentage is plotted against seeded cell number and
incubation time.
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Viability %

Seeded Cell # (x106)

Figure 9b NIH-3T3 Cell viability percentage. Cell viability is reported in percent of the
original seeded number Viability percentage is plotted against seeded cell number and DQgelatin concentration

Figure 10 Turkey Test analysis on percent cell viability of different seeded cell number.
Least square mean value represents cell viability percentage at the seeded cell number in milion
cell. Levels not connected by the same letters are statistically different.
51

3.2. Setting b)

Figure 11 Analysis of variance. ANOVA of setting b) signal-to-noise ratio in signal
optimization process; treating each specific condition; concentration and cell seeding number as
one treatment (n=3, p<0.05)

In these set of experiments, cell adhesion support scaffold is included into the assay to verify
their positive impact on cell viability and weather they cause changes in experimental results.
Analysis of varience suggest statistical significance between each group of experiments prepared
by varying seeded cell number, DQ-gelatin concentration and incubation time, Figure 11 (n=3,
p<0.05). Out of 144 conditions, 6 outliers were excluded. The constructed mathematical model
from compilation of signal-to-noise ratio data and statistical analysis has R2 of 0.82, figure 12a),
which is relatively high, thus it is possible for the model to closely predict the real values
experimental values. The mathematical model consist of terms listed in figure 12b), having
significance on the model according to the absolute value of their t Ratios.
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Figure 12a Mathematical model. Actual signal-to-noise data are displayed as black dots against
red predicted plot.

Figure 12b Mathematical model. Parameter estimates of each term that is used to generate
mathematical model.

53

0.962831 + (0.119493 * Days) + (1.437393 * Seeded Cell#) + (0.004032 * conc) +
[(-0.38034) * (Day-3)2] + [(0.209935) * (Day-3) * (Seeded Cell# - 0.370803)] +
[(-1.945501) * (Seeded Cell# - 0.370803)2] + [(0.000543) * (Day-3) * (conc – 22.518248)] +
[(0.000641) * (Seeded Cell# - 0.370803) * (conc – 22.518248)] +
[(-0.000107) * (conc – 22.518248)2]

Signal/noise

Figure 12c Mathematical model. Equation for the constructed mathematical model; Term
Seeded Cell # refers to seeded cell number, Days refer to incubation time and conc refers to DQgelatin concentration.

Figure 13a 3-Dimensional plot of signal-to-noise ratio. Signal-to-noise ratio data is plotted
against seeded cell number and DQ-gelatin concentration
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Signal/noise
Figure 13b 3-Dimensional plot of signal-to-noise ratio. Signal-to-noise ratio data is plotted
against seeded cell number and incubation time.

Reaction Time
(Day) (5)

Seeded Cell #
(x106) (0.8)

DQ-gelatin
(µg/mL) 50

Figure 13c 3-Dimensional plot of signal-to-noise ratio. Prediction profiler set at the condition
which produce highest signal-to-noise ratio. Red number indicates predicted optimal attainable
value.
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To study how seeded cell number, DQ-gelatin concentration and incubation time affect the
signal-to-noise ratio trend, the collected data are plotted against these factors and are displayed
as two 3-dimensional plots on figure 13. It is noticeable that the signal-to-noise ratio trend shifts
a little as one factor is varied. For example, the effect of seeded cell number increases as the
number of days and DQ-gelatin is increased. This could be visualized as the increase in steepness
of the slope when comparing the trend line between day 1 and day 5, and of DQ-gelatin
concentration at 5 and 50 µg/mL.

The slope increase may be caused by the more ease of access for cells when more DQ-gelatin
were available, therefore, there were more opportunities for DQ-gelatin degradation to take
place. Also, by prolonging the incubation period, there is longer time for cells to for cell
modulated proteolysis, as a result, the effect of seeded cell number are more pronounced.

On the prediction profiler, the trend at the condition that generates the highest signal-to-noise
ratio is displayed. From figure 13, the optimal condition would be the highest seeded cell,
highest DQ-gelatin concentration and the longest incubation time. The statistical significance of
each varied variables is verified by Tukey Test, figure 14. Changes in DQ-gelatin concentration
does not cause large distinction in resulting signal-to-noise ratio while changes in all levels of
seeded cell number and incubation time cause the resulting signal-to-noise ratio to be statistically
different in each conditions.
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Seeded Cell # (x106)

DQ-gelatin (µg/mL)

Reaction Time (Day)

Figure 14 Turkey Test analysis result. Turkey test were performed on percent cell viability of
different incubation time, seeded cell number and DQ-gelatin concentration. Least square mean
value represents cell viability percentage at the condition level in million cells. Levels not
connected by the same letters are statistically different.

Cell Viability Test
Following fluorescence measurement of signal optimization setting b), cell viability check was
conducted. Analysis of variance shows no statistical significant difference resulting from varying
seeded cell number, DQ-gelatin concentration and incubation time, (n=3, p=0.05), Figure 15.
Therefore, mathematical model of viable cell percentage will not been constructed for this
setting. From analysis of raw data, the viability percentage of the condition contributing to
highest signal-to-noise ratio is 251.48 ± 42.44% indicating that there is more than adequate
number of viable cells persisting throughout the experiment. Therefore, the concluded best
condition in signal optimization experiments setting b) is the condition with seeded cell number
of 0.8 million cells, 5 days incubation period and 50 µg/mL of DQ-gelatin concentration.
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Figure 15 Analysis of variance for cell viability of setting b) Anova on NIH-3T3 viability in
signal optimization setting b); treating each specific condition; concentration and cell seeding
number as one treatment (n=3, p<0.05). The analysis were not able to detect significant
difference between each conditions

3.3. Overall Results and Discussion
From our experiments, as the incubation time is extended, the level of background fluorescence
increases, therefore, our measured fluorescence data is converted to signal-to-noise ratio to
maintain the consistency and to report the distinctiveness of the emitted fluorescence.

In setting a) experiment without cell adhesion support scaffold, mathematical model for signalto-noise ratio indicates that the main contributing factor to signal-to-noise level is the seeded cell
number. But because the condition that contributes to higher signal range cannot maintain
satisfactory amount of cell viability, the governing mathematical model is the percent viability
model, not the model for signal-to-noise ratio. From percent viability model, the predicted
optimal conditions were the experiments with seeded cell number of 0.35 million cells incubated
with 25 µg/mL of DQ-gelatin for 15 hours with signal-to-noise ratio of 1.23 ± 4x10-2. This
deviates a little from the actual highest signal-to-noise ratio is 1.40 ± 0.05 from experiment with
seeded cell number of 0.35 million cells incubated with 10 µg/mL of DQ-gelatin for 10 hours.
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The optimal condition to pick from these options is somewhat questionable. All in all, because
the conditions with higher signal-to-noise ratio cannot support NIH-3T3 to remain viable, we
suggest seeking other alternatives for cell-based assay assembly instead of considering for best
options out of experiments from setting a).

In setting b) experiment with cell adhesion support scaffold, analysis of variance cannot detect
the significance between different treatment conditions thus reliable mathematical model cannot
be constructed. From rough cell viability data analysis, majority of the experiments provide
considerable capacity to maintain cell viability, e.g., over 80% viability. The mathematical
model for signal-to-noise ratio suggest the most suitable condition for signal optimization 0.8
million cells, 5 days incubation period and 50 µg/mL of DQ-gelatin concentration. This
suggestion agrees with the actual conducted experimental condition that generates the highest
signal-to-noise ratio of 2.67 ± 0.23. MTT test confirms the capacity of the cell adhesion scaffold
to prevent cell apoptosis by showing viability percentage of 251.48 ± 42.44%. By comparing
highest obtained signal-to-noise ratio and cell viability of setting a) and setting b), cell adhesion
scaffold play role in increasing signal-to-noise ratio and maintain cell viability therefore is worth
incorporating to be a part of the assay despite the reduction in practicality from assay
preparation.

From all experimental condition conducted, the highest attainable signal-to-noise ratio was 2.67
± 0.23. This small number coincides with what has been mentioned in Ravanti et al. that cells in
unstimulated culture express exceedingly low level of MMPs. With minute amount of MMPs,
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only small extent of florescence signal could be generated, resulting in low value of signal-tonoise ratio. Despite these concerns, the signal-to-noise ratios produced by different conditions
are all statistically different from background fluorescence. These results suggest that even
though those NIH-3T3S produce small amount of MMPs, it is adequate to generate statistically
distinct signal and therefore, it could be concluded that cell based assay is a feasible method for
semi-quantitative proteolytic degradation detection.
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4. Conclusion
The objective of assay optimization process is to identify the condition that is most practical to
prepare that provides the highest signal-to-noise ratio while retaining an acceptable number of
viable NIH-3T3 cell. The optimization process is conduct by culturing NIH-3T3 cells in presence
of DQ-gelatin which emits fluorescence signal proportional to its extent of degradation. The
number of seeded cell, DQ-gelatin concentration and the incubation time is varied. The
experiments in conducted in 2 sets; setting a) without cell adhesion support scaffold and b) with
the scaffold. This is done to verify the necessity of the scaffold.

The highest signal-to-noise ratio of the condition in setting a) that could maintain more than 80%
of originally seeded NIH-3T3 was 1.23 ± 4x10-2 while in setting b) the highest signal-to-noise
ratio is 2.67 ± 0.22. Therefore, we conclude that the cell adhesion support scaffold is a necessary
component of our assay the increases the capacity to retain cell viability and enhance the signal
intensity.

Because of the distinctive signal generated from cell driven DQ-gelatin breakdown and the high
percentage of maintained NIH-3T3, we anticipate that a cell-based assay that resembles proteinbased implant break down in vivo could be assembled. Upon introduction of MMPis the
breakdown of DQ-gelatin could be and the reduction in fluorescene emission could be measured.
The extent of fluorescence emission indicates the proteolytic inhibitory efficacy of the inhibitor.
Based on these assumptions, MMP inhibitor screening assay could be constructed and apply to
determine the suitability of the tested MMPs.
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The identified condition that provides the highest signal-to-noise ratio that can maintain NIH3T3 viability is the experiment in setting b) with seeded cell number of 0.8 million cells, 5 days
incubation period and 50 µg/mL of DQ-gelatin concentration. This condition will be used in
MMP inhibitor screening assay to determine the inhibitory effect that our selected MMP
inhibitors possess.
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CHAPTER 4: CELL-BASED MMP INHIBITOR SCREENING ASSAY
1. Rationale
After the optimal experiment condition has been determined, it is used to assemble our cellbased MMP inhibitor screening assay. NIH-3T3 is cultured on cell adhesion support scaffold at
0.8 million cells/well, in presence of 50 µg/mL DQ-gelatin with varying amount of MMP
inhibitor, determined in prototype optimization. After 5 days the emitted fluorescence is
measured at designate time point. This signal from culture without MMP inhibitor is used as a
control to compare with emitted signal from cultures with MMP inhibitor. When the inhibitor
binds to zinc binding domain of MMP, the enzyme proteolytic activity is deactivated leading to
reduction in fluorescence emission because of less degradation of DQ-gelatin has taken place.
From this logic, we believe the inhibitory effect of MMPi could be determined and used this
quantification as means for screening potential MMPi for protein based implant lifetime
prolongation.

The efficacy of the inhibitor is reported in percent reduction of fluorescence signal from culture
without MMP inhibitor. The more effective the inhibitor, the lower signal is generated. Selected
MMP inhibitors are added in a varied concentration to determine the optimal dosage. Cell
viability assay is performed to ensure high percentage of seeded NIH-3T3 remain alive
throughout the assay. Statistical analysis was performed to see the result precision, the
significance between each type of inhibitor and the difference in their inhibitory effect at
difference concentration.
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2. Methodology
2.1. Assay Preparation
Material required, reagent preparation, fibroblast culture, scaffold fabrication, and viability assay
were carried out as mentioned in the methodology section of chapter 3. MMP inhibitor screening
assay experiments take place in tissue culture treated black 96-well plate (VWR). Growth media
as used in signal optimization was mixed with 10X reaction buffer in 1:9 ratio to be used as
reaction buffer for diluting DQ-gelatin and cell suspension. NIH-3T3 were detached, spun-down
and made into high concentration cell suspension ready for seeding.

2.2. MMP Inhibitor Screening Assay
The MMP inhibitor screening assay took place in tissue culture treated black 96-well plate
(VWR). The fibronectin coated scaffolds were aspirate dried and inserted into each wells of three
96-well plates except the outer most rows. Cells were seeded into scaffold 0.8 million cells per
well. DQ-gelatin was dissolved in reaction buffer and transfer to 96-well plate to have final
concentration of 50 µg/mL. The concentration of BB-94 and TIMP-1 were varied from 20-1000
nM (9.55-477.64 ng/mL) and 0.1-2 µg/mL respectively. The total reaction volume in each well is
200 µL. Each condition was prepared in triplicated. The outer most rows were filled with sterile
filtered deionized water and the plates were wrapped in tin foil to prevent the plates from light
exposure. The 96-well plates were transferred into incubator and kept under standard tissue
culture conditions 5 days. At the designate time, the emitted signal is read using plate reader set
to read florescence with absorption maxima approximately at 495 nm and emission maxima
approximately at 515 nm.
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2.3. NIH-3T3 Viability Testing
After each time point measurement, the percent viability of NIH-3T3 for each condition was
quantified by MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide) assay
following the same method as in section 2.4. NIH-3T3 viability testing from previous chapter.
The estimate of viable cell number is proportional to the absorbance value at 570 nm.

2.4. Statistical Analysis
Numerical data for fluorescence signal and MTT viability assay were assessed by JMP Pro11/
statistical analysis package. Analysis of variance (ANOVA) were performed to determine
statistical significant between groups, i.e. inhibitor or concentration, followed by Tukey test once
significant difference were detected. Statistical significance was considered at p values of less
than 0.05.
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3. Result and Discussion
3.1. MMP Screening Assay
Following incubation of 50 µg/mL DQ-gelatin with NIH-3T3 in presence of either TIMP-1 or
BB-94 at different concentrations under standard tissue culture condition (5% CO2, 95%
humidity at 37°C) for 5 days, the emitted fluorescence was measured. TIMP-1 was tested at 0.1,
0.375, 0.75 and 2 µg/mL and BB-94 at 20, 250, 750 and 1000 nM. The ranges of MMP inhibitor
concentration were selected based on their potency under physiological conditions to elicit the
ability of our prototype in MMP inhibition detection not for efficacy comparison. Statistical
analysis suggests that the signal generated in consequence of culturing cells in presence of DQgelatin is significantly different from the background fluorescence (n=3, p<0.05), detail
discussion mentioned in prototype development.

From the 96-well plate used as experiment vessel, fluorescence emission from well containing
MMP inhibitor was compared to wells without inhibitors to visualize the enzyme inhibition
potency as the level of fluorescence correlated with the extent of DQ-gelatin break down. The
concentration of each inhibitor was varied, each condition were prepared in triplicates. The data
obtained is present as bar chart in the form of percentage of the DQ-gelatin degradation without
the inhibitory effect of MMP inhibitor (Figure 16). TIMP-1 demonstrated maximum inhibition
potency of 60.00±27.41 % at the concentration of 2 µg/mL and BB-94 displayed maximum
inhibition potency of 72.59±4.75 % at the concentration of 1000 nM.
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The initial assessment using Analysis of variance (ANOVA) considering each distinct condition,
type of inhibitor and concentration of inhibitor as one treatment shows significant difference
between different treatment (p<0.05), (Figure 17a). To determine which pairS of treatments are
statistically different another ANOVA and Tukey test were performed. The analysis suggests
that there is significant difference between the inhibitory effect of TIMP-1 and BB-94 (Figure
17b) but variation in their concentration does not influence the inhibitor efficacy in a significant
level (Figure 17c). To conclude the overall efficacy of both MMP inhibitors over the chosen
concentration range, TIMP-1 post 43.80±18.62% inhibitory effect while BB-94 shows
63.67±7.5% degradation inhibition over the experimental period of 5 days.

To compare inhibition efficacy of BB-94 and TIMP-1, BB-94 possesses higher inhibition
potency with smaller standard deviation. Because there are no detectable statistical difference in
the inhibitory effect of BB-94 the best concentration would be the lowest concentration, 20 nM.
Despite TIMP-1 does not have detectable significant difference between each concentration, T3
has no significant inhibitory effect, thus, it is best to select the concentration report to be most
potent, 2 µg/mL. As there is no statistical difference in the efficacy of these 2 conditions, it could
be roughly concluded that BB-94 is approximately 200 times more potent than TIMP-1 at
concentration 20 nM or approximately 9.55 ng/mL.
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Degradation of DQ-gelatin in presence of MMPi
% Degradation
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Figure 16a Degradation of DQ-gelatin and MMP inhibitor efficacy measurement.
Degradation of DQ-gelatin in presence of MMP inhibitor. Timp-1 and BB-94 were tested at
concentration 0.1, 0.375, 0.75 and 2 µg/mL and 20, 250, 750 and 1000 nM respectively.

Inhibition Effiency of MMPi
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Figure 16b Degradation of DQ-gelatin and MMP inhibitor efficacy measurement.
Inhibition efficacy of MMP inhibitor, the reduction from 100 percent degradation indicates the
inhibitory effect of TIMP-1 and BB-94. Values are mean ± SD; (n=3, *p≤0.05 vs. control)
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Figure 17a Statistical analysis. ANOVA of MMP inhibitor screening assay result; treating each
concentration of each inhibitor as one treatment (n=3, p<0.05)

Figure 17b Statistical analysis. b) ANOVA of MMP inhibitor screening assay result; treating
each type of inhibitor as one treatment (n=12, p<0.05)

Figure 17 Statistical analysis. Tukey test on cell viability of different conditions, levels not
connected by same letter are significantly different.
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3.2.NIH-3T3 Viability Testing

Figure 18 Analysis of variance on cell viability after MMP inhibitor screening assay.
ANOVA of NIH-3T3 viability; treating each specific condition; each type of inhibitor and the
concentration as treatment (n=3, p<0.05)

After MMP inhibitor screening assay was complete, fluorescence measurement taken, MTT
viability assay was performed to ensure cells remain alive throughout 5-day incubation period.
MTT solution was insert into each experimental compartment, mitochondrial dehydrogenase in
viable cells would convert yellow MTT into purple formazan crystal which could be detected by
measuring absorbance at 570 nm after solubilization. Analysis of variance shows no significant
difference between each conditions (n=3, p=0.05), Figure 18 over 5 days, NIH-3T3 in each
condition had proliferated to 238±35.17% the original seeded cell number. These results suggest
that our assay gave satisfactory performance in maintaining cell viability throughout the
experiment period.
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4. Conclusion
The purpose of Cell-based MMP inhibitor screening assay experiments is to observe whether our
developed assay could display the inhibitory potential of our selected MMP inhibitors as we have
postulated. We hypothesized that the introduction of MMP inhibitor would reduce the proteolytic
activity within the experimental volume, which could be determined by the reduction of emitted
fluorescence caused by DQ-gelatin breakdown. Experiment were carried out using the optimized
conditions obtained from novel assay development process, 0.8 million cells seeded on scaffold
incubated for 5 days in presence of 50 µg/mL of DQ-gelatin, together with varied concentrations
of MMP inhibitors; 0.1-2 µg/mL and 20-1000 nM for Timp-1 and BB-94. The outcomes were of
satisfactory that each experiment containing MMP inhibitor shows reduction in fluorescence
signal when compare to the control group that has no MMP inhibitor within the experiment.
TIMP-1 exhibit maximum inhibition potency of 60.00±27.41 % at the concentration of 2 µg/mL
and BB-94 72.59±4.75 % at the concentration of 1000 nM after 5 days incubation. From these
results, we conclude that our constructed novel cell-based assay could be used to determine the
efficacy in impeding proteolytic activity and thus be utilized as a tool for MMP inhibitor
screening.
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CHAPTER 5: CONCLUSION AND RECOMMENDATION FOR FUTURE RESEARCH
We believe that based on fluorescence emission emitted from DQ-gelatin we could estimate the
inhibitory efficacy of MMPi in protein proteolysis and use this concept to construct MMP
inhibitor screening assay. From assay prototype development, it has been demonstrated that cell
driven breakdown of DQ-gelatin created a reliable fluorescent signal that is statistically different
from the background noise. The most favorable condition for signal optimization that can
maintain NIH-3T3 viability defined during the development is used as the setting for MMP
inhibitor screening assay.

The efficacy BB-94 and TIMP-1, our MMP inhibitor of choice were examined. The
concentration range of these inhibitor were based on the estimate value of MMP in tissue and
their half maximal inhibitory concentration value; Timp-1 0.1-2 µg/mL and BB-94 20-1000 nM
or 9.55-477.64 ng/mL. After 5 days incubation of 0.8 million NIH-3T3 cells in presence of 50
µg/mL DQ-gelatin with varying amount of MMP inhibitor, the fluorescence signal is measured.
The signal was translated into the percentage of the fluorescence signal emitted by the control
where no inhibitor was added and the decrease in the value is reported as the inhibitor efficacy of
the inhibitor.

From our assay, TIMP-1 exhibit maximum inhibition potency of 60.00±27.41 % at the
concentration of 2 µg/mL and BB-94 72.59±4.75 % at the concentration of 1000 nM. The
statistical analysis showed no significant difference between each concentration of inhibitors.
Therefore, to conclude our result, the overall inhibitory efficacy of MMP inhibitors over the
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chosen concentration range for TIMP-1 is 43.80±18.62% and BB-94 is 63.67±7.5% over the
experimental period of 5 days. BB-94 proves to be the more attractive potential MMP inhibitor
for implant lifetime prolongation with its higher inhibitory efficacy, less in result variations and
relatively lower cost.

By being capable of displaying optimal concentration and efficacy of MMPi while maintaining
cell viability we believe our novel cell-based assay is a feasible assay for inhibitor screening that
represents the complex degradation process of protein based implant in biological system better
than the current conventional enzyme-based methods. Because of the high cost of MMPs, our
assay may serve as a less costly alternative and would shorten the process of cytotoxicity test if
the chosen MMP inhibitor would later be tested in the in vivo experiment.

For future directions, the improvements of the novel assay could be conducted by simplifying
cell adhesion support scaffold fabrication process by changing types of materials and optimizing
their capacity to support viability of high cell number. In this way, the assay would gain more
practicality and would be more easy to use.

Other than the capability of the assay, from this research, we may be able to conclude that MMP
inhibitors may be used to impede protein degradation process, thus, is a potential substance that
could be used to be co-delivered with protein based material to extend the implant retention time
in vivo. Further researches are required to before this scheme may successfully take place. As
MMP are crucial for ECM remodeling process which is a natural mechanism which should go
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uninterrupted, introducing MMP without retaining them to the implant cite may bring about
negative side effects. Furthermore because MMP modulated proteolytic degradation is confined
to a close space near cell periphery [56], MMPi efficacy would detrimentally decrease if let
dispersed to surrounding area. For this reason, introduction of MMP inhibitor may be a feasible
means of extending lifetime of protein based implants but there is still considerable distance
before their actual usage. A proper conjugation method to couple MMP inhibitor to the implants
may be the crucial next step towards the particular improvements in therapeutic efficacy.
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